Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AbbVie is conducting a study titled ‘Effectiveness and Safety of Venetoclax in Combination With Azacitidine in Patients With Acute Myeloid Leukemia in Real Life Clinical Practice’ to evaluate the treatment of acute myeloid leukemia (AML) in adults in Colombia. The study aims to assess the effectiveness and safety of venetoclax combined with azacitidine, a treatment already approved for AML.
The intervention involves administering venetoclax orally and azacitidine either subcutaneously or intravenously. This combination is intended to improve treatment outcomes for AML patients.
The study is observational with a cohort model and a prospective time perspective. It is designed to fit within routine clinical practice without additional burdens on participants.
The study began on November 30, 2023, with an estimated duration of 36 months. The last update was submitted on July 9, 2025. These dates are crucial as they guide the study’s progress and expected completion.
This update could positively impact AbbVie’s stock performance by reinforcing investor confidence in its oncology portfolio. The study’s success may also influence the competitive landscape in AML treatment.
The study is currently recruiting, and further details are available on the ClinicalTrials portal.